DOP2009000282A - Polipeptido ace2 - Google Patents

Polipeptido ace2

Info

Publication number
DOP2009000282A
DOP2009000282A DO2009000282A DO2009000282A DOP2009000282A DO P2009000282 A DOP2009000282 A DO P2009000282A DO 2009000282 A DO2009000282 A DO 2009000282A DO 2009000282 A DO2009000282 A DO 2009000282A DO P2009000282 A DOP2009000282 A DO P2009000282A
Authority
DO
Dominican Republic
Prior art keywords
ace2 polypeptide
ace2
polypeptide
dimero
glycosilated
Prior art date
Application number
DO2009000282A
Other languages
English (en)
Inventor
Manfred Schuster
Hans Loibner
Evelyne Janzek-Hawlat
Bernhard Peball
Stefan Stranner
Bettina Wagner
Robert Weik
Original Assignee
Apeiron Biologics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08450052A external-priority patent/EP2108695A1/de
Application filed by Apeiron Biologics Ag filed Critical Apeiron Biologics Ag
Publication of DOP2009000282A publication Critical patent/DOP2009000282A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE TRATA DEL POLIPEPTIDO RECOMBINANTE ACE2, PRESENTE COMO UN DIMERO FORMADO ESPECIFICAMENTE DE MONOMEROS GLICOSILADOS Y SE USA PARA PRODUCIR PRODUCTOS FARMACEUTICOS CON UNA VIDA MEDIA PROLONGADA
DO2009000282A 2007-06-12 2009-12-11 Polipeptido ace2 DOP2009000282A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0091307A AT505262A1 (de) 2007-06-12 2007-06-12 Rekombinantes ace2 polypeptid
EP08450052A EP2108695A1 (de) 2008-04-08 2008-04-08 Ace2 Polypeptid

Publications (1)

Publication Number Publication Date
DOP2009000282A true DOP2009000282A (es) 2010-03-31

Family

ID=39720296

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2009000282A DOP2009000282A (es) 2007-06-12 2009-12-11 Polipeptido ace2

Country Status (35)

Country Link
US (3) US8586319B2 (es)
EP (3) EP2543724B1 (es)
JP (1) JP5731193B2 (es)
KR (2) KR101682240B1 (es)
CN (2) CN104450654A (es)
AT (1) AT505262A1 (es)
AU (1) AU2008261591B2 (es)
BR (1) BRPI0813942B8 (es)
CA (1) CA2692854C (es)
CO (1) CO6270265A2 (es)
CR (1) CR11213A (es)
CY (2) CY1116873T1 (es)
DK (2) DK2543724T3 (es)
DO (1) DOP2009000282A (es)
EA (1) EA027399B1 (es)
EG (1) EG27095A (es)
ES (2) ES2550390T3 (es)
HK (2) HK1255493A1 (es)
HR (2) HRP20151120T1 (es)
HU (2) HUE037877T2 (es)
IL (1) IL202653B (es)
LT (1) LT2543724T (es)
MA (1) MA31472B1 (es)
MX (1) MX2009013472A (es)
MY (1) MY180672A (es)
NO (1) NO2543724T3 (es)
NZ (1) NZ581704A (es)
PL (2) PL2543724T3 (es)
PT (2) PT2155871E (es)
RS (2) RS57292B1 (es)
SI (2) SI2543724T1 (es)
TR (1) TR201808117T4 (es)
UA (1) UA106869C2 (es)
WO (1) WO2008151347A1 (es)
ZA (1) ZA200908751B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
EP2077119A1 (de) * 2007-12-21 2009-07-08 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Behandlung von Fibrosen und Lebererkrankungen
AT506632A1 (de) * 2008-04-09 2009-10-15 Apeiron Biolog Forschungs Und Behandlung von tumorerkrankungen
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
JP2015520128A (ja) 2012-04-19 2015-07-16 オプコ バイオロジクス リミテッド 長時間作用性オキシントモジュリン変異体とその作製方法
ES2633894T3 (es) 2012-08-02 2017-09-25 F. Hoffmann-La Roche Ag Procedimiento para producir moléculas monoméricas y multiméricas y usos de las mismas
KR102202255B1 (ko) 2012-11-20 2021-01-13 옵코 바이오로직스 리미티드 생식샘자극 호르몬 카복시 말단 펩타이드들과 부착하여 폴리펩타이드들의 유체역학적 부피를 증가시키는 방법
US9757433B2 (en) 2013-01-14 2017-09-12 Apeiron Biologicals AG Modified ACE2 polypeptides
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
US10960058B2 (en) 2015-06-19 2021-03-30 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
CN118085104A (zh) 2016-07-11 2024-05-28 Opko生物科学有限公司 长效凝血因子及其制备方法
US11518788B2 (en) * 2020-07-10 2022-12-06 Avirus, Inc. Methods and compositions for treating and preventing viral infection
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
EP3884957A1 (en) 2020-03-26 2021-09-29 The University of British Columbia Methods for treatment of virus and methods for screening of anti-virus reagent using organoids
US20230174611A1 (en) * 2020-04-24 2023-06-08 Administrators Of The Tulane Educational Fund Compositions and methods for preventing or reducing the effects of infections by coronaviruses that bind the extracellular domain of the ace2 receptor
CN113667016A (zh) * 2020-05-15 2021-11-19 普米斯生物技术(珠海)有限公司 一种构建冠状病毒抗体的平台
WO2021247675A1 (en) 2020-06-02 2021-12-09 Ngm Biopharmaceuticals, Inc. Coronavirus-binding agents and uses thereof
DE102020207224A1 (de) 2020-06-09 2021-12-09 Christoph Karle Protein oder Peptid, insbesondere zur Prophylaxe und/oder Behandlung einer durch Coronaviren, insbesondere SARS-CoV-2-Viren, hervorgerufenen Infektion oder Infektionskrankheit und/oder einer Folgekrankheit davon
JP2023531368A (ja) * 2020-06-25 2023-07-24 グリックニック インコーポレイテッド Ａｃｅ２－ｆｃ融合タンパク質および使用方法
WO2022008642A1 (en) 2020-07-08 2022-01-13 Apeiron Biologics Ag Treatment of sars-cov-2 infection with a combination of targets
MX2023000504A (es) * 2020-07-10 2023-04-14 Biomolecular Holdings Llc Anticuerpos tetrahedricos.
WO2022037699A1 (en) * 2020-08-21 2022-02-24 Westlake University Engineered ace2 oligomers and uses thereof
CN112280764A (zh) * 2020-11-18 2021-01-29 通用生物系统（安徽）有限公司 一种新冠重组ace2蛋白在哺乳动物细胞中的生产方法
EP4011387A1 (en) 2020-12-11 2022-06-15 IMBA-Institut für Molekulare Biotechnologie GmbH Superior neutralization of sars-cov-2 by deglycosylated human angiotensin converting enzyme 2
WO2022159433A1 (en) 2021-01-20 2022-07-28 Singh Biotechnology, Llc Therapeutics directed against coronavirus
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
WO2022207918A1 (en) 2021-04-02 2022-10-06 Apeiron Biologics Ag COVID-19 Therapy
EP4387732A1 (en) 2021-08-19 2024-06-26 Phenom Pharmaceuticals, inc. Compositions and methods for treatment of sars cov-2
CN113897346A (zh) * 2021-09-16 2022-01-07 四川大学 能够提高与SARS-CoV-2 S蛋白亲和力的ACE2突变组合及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989363B1 (en) * 1997-12-11 2006-01-24 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6610497B1 (en) * 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6194556B1 (en) * 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
SI1515752T1 (sl) * 2002-06-19 2009-06-30 Univ Health Network Aktivacija ACE2 za zdravljenje srčne, pljučne in ledvične bolezni in hipertenzije
AU2003276877A1 (en) 2002-09-09 2004-03-29 Millenium Pharmaceuticals, Inc. Crystal structure of angiotensin-converting enzyme-related carboxypeptidase
EP1723962A1 (en) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
AT504443B1 (de) 2006-10-19 2008-11-15 Apeiron Biolog Forschungs Und Verfahren zur bestimmung der aktivität von ace2
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
EP2108695A1 (de) 2008-04-08 2009-10-14 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Ace2 Polypeptid
AT506258A1 (de) * 2007-12-18 2009-07-15 Apeiron Biolog Forschungs Und Behandlung inflammatorischer krankheiten
AT506632A1 (de) * 2008-04-09 2009-10-15 Apeiron Biolog Forschungs Und Behandlung von tumorerkrankungen

Also Published As

Publication number Publication date
US8586319B2 (en) 2013-11-19
TR201808117T4 (tr) 2018-07-23
AU2008261591B2 (en) 2014-08-07
IL202653A0 (en) 2011-08-01
CA2692854A1 (en) 2008-12-18
PT2543724T (pt) 2018-06-11
EP2543724B1 (de) 2018-03-21
US10716833B2 (en) 2020-07-21
DK2543724T3 (en) 2018-05-28
BRPI0813942A2 (pt) 2014-12-30
RS57292B1 (sr) 2018-08-31
EA201000002A1 (ru) 2010-08-30
CY1120426T1 (el) 2019-07-10
EP2543724A3 (de) 2013-02-20
JP2011519264A (ja) 2011-07-07
ES2670938T3 (es) 2018-06-04
EA027399B1 (ru) 2017-07-31
WO2008151347A1 (de) 2008-12-18
PT2155871E (pt) 2015-10-26
BRPI0813942B1 (pt) 2019-08-20
CN104450654A (zh) 2015-03-25
MY180672A (en) 2020-12-05
DK2155871T3 (en) 2015-11-09
JP5731193B2 (ja) 2015-06-10
HRP20151120T1 (en) 2015-11-20
HUE028012T2 (en) 2016-11-28
ES2550390T3 (es) 2015-11-06
SI2543724T1 (en) 2018-07-31
LT2543724T (lt) 2018-06-25
US20180289779A1 (en) 2018-10-11
ZA200908751B (en) 2010-07-28
KR101682240B1 (ko) 2016-12-06
CA2692854C (en) 2017-07-04
US20140099297A1 (en) 2014-04-10
EP3375872A1 (de) 2018-09-19
KR20100040809A (ko) 2010-04-21
PL2155871T3 (pl) 2015-12-31
MX2009013472A (es) 2010-06-25
EP2543724A2 (de) 2013-01-09
NO2543724T3 (es) 2018-08-18
CY1116873T1 (el) 2017-04-05
NZ581704A (en) 2012-05-25
RS54340B1 (en) 2016-02-29
BRPI0813942B8 (pt) 2021-05-25
KR20160054045A (ko) 2016-05-13
EG27095A (en) 2015-05-28
PL2543724T3 (pl) 2018-08-31
UA106869C2 (uk) 2014-10-27
US20100310546A1 (en) 2010-12-09
AT505262A1 (de) 2008-12-15
SI2155871T1 (sl) 2015-11-30
CR11213A (es) 2010-04-20
HRP20180856T1 (hr) 2018-08-24
EP2155871A1 (de) 2010-02-24
HUE037877T2 (hu) 2018-09-28
AU2008261591A1 (en) 2008-12-18
HK1136602A1 (en) 2010-07-02
CO6270265A2 (es) 2011-04-20
EP2155871B1 (de) 2015-08-12
MA31472B1 (fr) 2010-06-01
CN101796183A (zh) 2010-08-04
HK1255493A1 (zh) 2019-08-16
IL202653B (en) 2018-01-31

Similar Documents

Publication Publication Date Title
DOP2009000282A (es) Polipeptido ace2
GT201400033A (es) Pirimidinas anilladas sustituidas y uso de las mismas
AU340644S (en) Inspection lamp
CA144867S (en) Candle holder
GB201220508D0 (en) production of fuels, chemicals, and amino acids
AU343303S (en) Wake up light
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
AU338916S (en) Luminaire
AU340643S (en) Inspection lamp
CL2013002601A1 (es) Uso de 1-desoxigalactonojirimicina y una terapia de reemplazo de enzimas con alfa-gal a para tratar la enfermedad de fabry.
MX2020003096A (es) Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif.
AR095977A1 (es) Un procedimiento para aumentar la formación de ácido piroglutámico de una proteína
CU20130057A7 (es) Polipéptidos del factor ix modificados y usos de los mismos
BR112013028187A2 (pt) processo para produzir olefinas
UY34181A (es) Metodo para ajustar la relacion entre el hidrogeno y el monoxido de carbono del gas sintetico
UY34357A (es) Productos gelificados probióticos o simbióticos y procedimiento para su obtención
UY34186A (es) ?procedimiento para revestir una superficie con micelas y superficie revestida con micelas?.
RU2011135537A (ru) Штамм enterococcus hirae, используемый при производстве кисломолочных продуктов
AU336457S (en) Lamp
UY34902A (es) Forma cristalina de un derivado de indolinona y su uso
PE20151206A1 (es) Polipeptidos del factor vii de accion corta
BR112016013461A2 (pt) microrganismo corineforme com uma capacidade melhorada para produzir l-lisina, e método para produzir l-lisina
AU339710S (en) LED lamp
AU339137S (en) Lamp
HN2010002052S1 (es) Blanco para una llave